Cargando…
Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review
Background: Clozapine is the antipsychotic of choice for treatment-resistant schizophrenia and has minimal risk for extrapyramidal symptoms. Therapeutic benefits, however, are accompanied by a myriad of cardiometabolic side-effects. The specific reasons for clozapine's high propensity to cause...
Autores principales: | Yuen, Jessica W. Y., Kim, David D., Procyshyn, Ric M., White, Randall F., Honer, William G., Barr, Alasdair M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893810/ https://www.ncbi.nlm.nih.gov/pubmed/29670504 http://dx.doi.org/10.3389/fnins.2018.00203 |
Ejemplares similares
-
A Focused Review of the Metabolic Side-Effects of Clozapine
por: Yuen, Jessica W. Y., et al.
Publicado: (2021) -
A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021) -
Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis
por: Lee, Lik Hang N., et al.
Publicado: (2018) -
Efficacy and tolerability of aripiprazole versus D(2) antagonists in the early course of schizophrenia: a systematic review and meta-analysis
por: Kim, David D., et al.
Publicado: (2021) -
Developing prediction models for symptom severity around the time of discharge from a tertiary-care program for treatment-resistant psychosis
por: Lee, Lik Hang N., et al.
Publicado: (2023)